

relationships by Spearman'. Response to smoking cessation was determined by paired Wilcoxon.

**Results** *Vastus lateralis* protein carbonyls were related to klotho levels ( $r = 0.34$ ,  $p = 0.02$ ). Patients with a low FFMI ( $n = 12$ ) had increased klotho levels compared to those who did not, 14.0 (8.5, 30.0) v 9.2 (6.5, 13.2) pg/mg;  $p = 0.04$ , however, protein carbonyls were not different ( $p = 0.08$ ). Conversely, patients with muscle weakness defined as a QMVC/BMI below 1.2 ( $n = 24$ ) had higher protein carbonylation, 0.76 (0.52, 0.99) v 0.51 (0.40, 0.71) nmol/mg;  $p = 0.04$ , but no difference in klotho (see figure 1). Patients with both a low FFMI and QMVC/BMI ( $n = 6$ ) had elevated levels of klotho and protein carbonyls ( $p = 0.02$  and  $p = 0.03$  respectively). In those completing smoking cessation, protein carbonyls, tended to fall, 0.75 (0.64, 1.24) to 0.61 (0.50, 0.71) nmol/mg;  $p = 0.08$ , however, klotho levels did not change ( $p = 0.38$ ).

**Conclusions** Klotho levels are related to oxidative stress within the quadriceps. Klotho levels are unexpectedly higher in those with reduced FFMI without increased oxidative stress. However, when there is loss of muscle mass and strength, increased klotho levels in muscle are accompanied by increased oxidative stress. Klotho may have a protective role against chronic oxidative stress in the skeletal muscle of patients with a reduced FFMI.

#### S52 MIR-181 INCREASES IN THE QUADRICEPS MUSCLE OF COPD PATIENTS AFTER AN ACUTE BOUT OF EXERCISE

<sup>1</sup>AVJ Donaldson, <sup>1</sup>RJ Tanner, <sup>1</sup>CA Davey, <sup>1</sup>N Hopkinson, <sup>1</sup>W D-C Man, <sup>2</sup>PR Kemp, <sup>1</sup>MI Polkey; <sup>1</sup>NIHR Respiratory Biomedical Research Unit of Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK; <sup>2</sup>Imperial College, London, UK

10.1136/thoraxjnl-2013-204457.59

**Introduction** MicroRNAs (miRs) are small non-coding RNAs that regulate gene expression and have been implicated in the control of skeletal muscle phenotype. Our group has previously shown that muscle-specific miRs are altered, and correlate with physiological parameters in the quadriceps<sup>1</sup> and plasma<sup>2</sup> of COPD patients. MiRs may therefore have a mechanistic role in the development of skeletal muscle dysfunction in COPD.

We hypothesised that muscle-specific miRs are involved in skeletal muscle adaptation to exercise and that changes in quadriceps miR expression after acute exercise would differ between patients and controls.

**Methods** 20 COPD patients and 11 controls were studied. Fasted quadriceps biopsies were taken before and one hour after an incremental, symptom limited, cycle exercise test. Muscle-specific miR-1, -499, -133, and -206 as well as miR-181, a more widely expressed miR associated with inflammatory responses, were quantified using qPCR. Paired analyses were performed using paired T-test or paired Wilcoxon.

**Results** See table of characteristics (Table 1)

##### Muscle miR results:

MiR-1, -499, -133 did not change with exercise. MiR-181 increased x1.5 in the COPD patients only one hour after exercise ( $p = 0.017$ , controls  $p = 0.83$ ). There was also a trend for miR-206 to increase in the COPD group only ( $p = 0.07$ ).

**Conclusions** Muscle-specific miRs do not change one hour after an acute bout of exercise in COPD patients or controls. However, miR-181 increased in the quadriceps of COPD patients. MiR-181 is not restricted to, but functions in muscle, and in addition has been shown to be linked to inflammatory signalling. The difference in the response of miR-181 expression to exercise

is consistent with COPD patients having a greater inflammatory response to exercise stimulus than controls.

#### REFERENCES

- Lewis A, et al *Thorax* 2012;67:26–34
- Donaldson AVJ et al *Thorax* 2013; Epub 28/06/2013

Abstract S52 Table 1. Table of characteristics.

Mean (SD) or Median (IQR)			significance of difference
	COPD	Control	
			*( $p < 0.05$ ) ** ( $p = < 0.01$ ) ***( $p = < 0.001$ )
Number	20	11	
Male (female)	13 (7)	6 (5)	
Age (years)	65.9 (9.1)	62.8 (7.2)	ns
FFMI (kg/m <sup>2</sup> )	18.2 (2.7)	17.9 (3.1)	ns
FEV1 (% pred)	56.5 (22.4)	103.6 (13.7)	
Best MVC (kg)	31.38 (9.5)	31.0 (6.5)	ns
average daily step count	4721 (6421,2453)	9140 (12635, 5682)	**
Workload, (watt, % pred)	69.9 (28.8)	146 (34.1)	***
V'O <sub>2</sub> l/min max	76.0 (21.6)	110.5 (16.9)	***
exercise (% pred)			

#### S53 STUDYING FIBRE SPECIFIC GENE EXPRESSION IN COPD USING LASER CAPTURE MICRO-DISSECTION IN HUMAN SKELETAL MUSCLE

<sup>1</sup>D Mohan, <sup>2</sup>A Lewis, <sup>1</sup>MS Patel, <sup>1</sup>K Curtis, <sup>1</sup>R Tanner, <sup>2</sup>P Kemp, <sup>1</sup>MI Polkey; <sup>1</sup>NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College, London, UK; <sup>2</sup>Section of Molecular Medicine, National Heart and Lung Institute, Imperial College London, London, UK

10.1136/thoraxjnl-2013-204457.60

**Background** Approximately 30% of patients with Chronic Obstructive Pulmonary Disease (COPD) exhibit peripheral skeletal muscle dysfunction and a shift towards type II glycolytic fibres in the quadriceps compared to healthy controls (Nanatek et al, 2013). Previous work to elucidate the molecular mechanisms underlying these changes has relied on whole biopsy samples and may have missed fibre-specific pathways; thus a method to evaluate fibre specific signalling pathways would be useful.

**Objective** To describe a novel laser capture micro-dissection (LCM) method to examine fibre-specific signalling in quadriceps biopsies.


**Methods** First larger Intercostal muscle biopsies were used to validate the methodology since they yielded more RNA. Fibres were classified as type-2 positive or type-2 negative based on immunoreactivity with a type-2 fibre specific anti-myosin Heavy Chain Alexa FLUOR 488 antibody. The type-2 negative fibre population was hence assumed to contain type-1 fibres, which was confirmed by the type-2 negative fibre population exhibiting a higher myhc7/2 mRNA ratio and expressing higher levels of genes associated with type-1 fibres, e.g. TNNT-1 and STARS, and lower levels of genes associated with type-2 fibres, e.g. TGF-B, myostatin, GAPDH and HDAC-4 ( $n = 2$ ).

We then examined OCT-embedded *vastus lateralis* muscle biopsy specimens. 10micron cryosections underwent fixation with 4% paraformaldehyde before immunostaining. LCM (PALM Microbeam, Zeiss, UK) was used to capture type I and type II fibre populations, before RNA extraction with RNAeasy FFPE kit (Qiagen, USA) and rtPCR to obtain cDNA. Sybr-II

qPCR was performed on fibre populations for target genes MHC I, MHC IIa, MHC IIx, HDAC-4 and RPLPO.

**Results** Preliminary results from three 10micron slices indicate that this technique is feasible to study fibre-specific signalling in COPD. LCM following immunostaining captures distinct fibre populations (Figure 1) confirmed by a higher MHC I content in 'type I fibres', with 'type II' fibres containing more MHC IIa, MHC IIx and HDAC-4 as would be expected. Gene expression is normalised against RPLPO.

**Conclusion** LCM can be used to study fibre specific inflammatory signalling in the skeletal muscle of COPD patients and immunostaining with MHC antibodies is a feasible way to distinguish between fibre types when capturing composite fibre populations.



**Abstract S53 Figure 1.** Gene expression (normalised for RPLPO) for Type I (red) and Type II (blue) quadriceps muscle fibres in COPD using three 10 micron sections for Laser Capture Micro-Dissection. Fold difference compared to type I fibres shown

#### S54 PRESERVATION OF MITOCHONDRIAL OXIDATIVE CAPACITY IN CRITICALLY ILL PATIENTS BALANCES REDUCTION IN MITOCHONDRIAL BIOGENESIS

R Astin<sup>1</sup>, Z Puthuchery<sup>1</sup>, S Saeed<sup>2</sup>, C Velloso<sup>3</sup>, M McPhail<sup>4</sup>, J Rawal<sup>1</sup>, J Skipworth<sup>1</sup>, M Singer<sup>2</sup>, S Harridge<sup>3</sup>, H Montgomery<sup>1</sup>, N Hart<sup>5</sup>; <sup>1</sup>Institute for Human Health and Performance, University College London, London, United Kingdom<sup>1</sup>; <sup>2</sup>Bloomsbury Institute for Intensive Care Medicine, University College London, London, United Kingdom<sup>2</sup>; <sup>3</sup>Centre of Human and Aerospace Physiological Sciences, King's College London, London, United Kingdom<sup>3</sup>; <sup>4</sup>Department of Medicine, Imperial College London, London, United Kingdom<sup>4</sup>; <sup>5</sup>Lane Fox Clinical Respiratory Physiology Research Centre, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom<sup>5</sup>

10.1136/thoraxjnl-2013-204457.61

**Background and Aims** In severe sepsis, early mitochondrial dysfunction in skeletal muscle is associated with decreased biogenesis and adverse patient outcome. We hypothesised that reduction in mitochondrial content during critical illness would be balanced by enhanced capacity to produce ATP achieved by switching from glucose to fatty acid oxidation as the preferred metabolic substrate.

**Methods** 30 critically ill patients (70% male, age  $56.4 \pm 19.7$  years, APACHE II score  $22.4 \pm 6.6$ ) were prospectively recruited <24 hours following intensive care admission from August 2009 to April 2011. Quadriceps vastus lateralis muscle biopsies were taken on day 1 and 7 and concentrations of mitochondrial respiratory complex proteins and key proteins of the -oxidation pathway were determined using a Luminex assay

normalised to an internal control (NNT). Mitochondrial DNA content (mtDNA), PGC1- $\alpha$  and PPRC mRNA concentrations were determined contemporaneously by RT-qPCR.

**Results** There were reduction in both skeletal muscle mtDNA ( $p = 0.04$ ) and PGC1- $\alpha$  ( $p = 0.02$ ) from day 1 to day 7, with fold change in PGC1- $\alpha$  correlated with the fold change in mtDNA ( $r^2 = 0.65$ ,  $p < 0.001$ ,  $n = 19$ ). PGC1- $\alpha$  and PPRC did not change. In ICU survivors, neither PGC1- $\alpha$  or mtDNA fold change predicted hospital or 18 month mortality ( $p > 0.1$ ). Protein levels of mitochondrial respiratory complexes I-V did not change significantly from day 1 to day 7 and mtDNA fold change did not correlate with fold change in complex I-V ( $p > 0.1$ ). There was a weak positive correlation between feeding (protein delivered) and fold change in complex I ( $r^2 = 0.20$ ,  $p = 0.014$ ) and complex III protein level ( $r^2 = 0.20$ ,  $p = 0.016$ ). Overall levels of mitochondrial -oxidation pathway proteins (CPT1, MCAD, ETF, DecR1) did not change whilst peroxisomal MEFII increased significantly ( $p < 0.01$ ).

**Conclusion** These data suggest decreased mitochondrial biogenesis over the first week of critical illness. The increase in -oxidation proteins combined with the lack of change in respiratory chain complex concentrations during the first week suggests that the oxidative capacity of the remaining mitochondria was enhanced with increased capacity to metabolise fatty acids. These data support our hypothesis that the decreased cellular energy utilisation accompanying decreased mitochondrial biogenesis is offset by increased capacity to produce ATP through the -oxidation of fats.

#### S55 MIR-181: A POTENTIAL BIOMARKER OF ACUTE MUSCLE WASTING?

<sup>1</sup>SAA Bloch, <sup>1</sup>PR Kemp, <sup>2</sup>MJD Griffiths, <sup>2</sup>MI Polkey; <sup>1</sup>NHLI, Imperial College, London, UK; <sup>2</sup>Royal Brompton and Harefield NHS Trust, London, UK

10.1136/thoraxjnl-2013-204457.62

**Introduction and Objectives** Acute muscle wasting in the critically ill is common and associated with significant morbidity and mortality. Although some aetiological risk factors are recognised it is difficult to predict those who will develop muscle wasting. The ability to predict who will go on to develop muscle wasting or to detect muscle wasting prior to it becoming clinically significant would provide the opportunity to intervene at an early stage with strength training or anabolic agents.

MicroRNAs are small non coding RNA that are thought to modulate post transcriptional regulation of translation. Since we have previously found that microRNA expression in skeletal muscle relates to muscle weakness in COPD (*Thorax* 2012;67:26-34) and in blood are associated with skeletal muscle phenotype (*Thorax* in press PMID 23814167) we hypothesised that plasma microRNAs could be biomarkers of ICU acquired muscle weakness.

**Methods** In a prospective observational study (*Crit Care Med* 2013;41:982-989) of 42 patients undergoing elective high-risk cardiothoracic surgery plasma levels of selected microRNAs were assayed pre-operatively and over the first week post operatively. Those who developed muscle wasting were identified by ultrasound.

**Main Results** 55% (23 of the 42) of patients developed muscle atrophy. Rise in mir-181 was significantly higher at day 2 post surgery in those who developed muscle wasting compared to those who did not ( $p = 0.03$ , figure 1). A rise in mir-181 of greater than 1.7 times baseline at day 2 post surgery has a 90%